Swedbank AB Lowers Position in Globus Medical, Inc. $GMED

Swedbank AB lessened its stake in Globus Medical, Inc. (NYSE:GMED) by 21.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 530,403 shares of the medical device company’s stock after selling 148,672 shares during the quarter. Swedbank AB’s holdings in Globus Medical were worth $46,309,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. William Blair Investment Management LLC lifted its holdings in shares of Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after buying an additional 414,134 shares in the last quarter. Sculptor Capital LP lifted its holdings in shares of Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock worth $162,936,000 after buying an additional 667,850 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after buying an additional 1,908,795 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Globus Medical by 72.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock worth $115,166,000 after buying an additional 842,547 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Globus Medical by 8.3% in the third quarter. Marshall Wace LLP now owns 1,711,909 shares of the medical device company’s stock worth $98,041,000 after buying an additional 131,433 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Up 0.0%

Globus Medical stock opened at $84.84 on Monday. The company has a market cap of $11.52 billion, a price-to-earnings ratio of 19.73, a PEG ratio of 1.75 and a beta of 1.00. The firm’s fifty day moving average is $87.26 and its 200 day moving average is $87.99. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Transactions at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 18.38% of the stock is currently owned by insiders.

Analysts Set New Price Targets

GMED has been the topic of several research analyst reports. Barclays boosted their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Truist Financial set a $115.00 target price on shares of Globus Medical in a report on Wednesday, February 25th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Finally, Royal Bank Of Canada upped their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.